EU Suspends Ranitidine Medicines
Executive Summary
In addition to deciding to suspend ranitidine-containing medicines, the European Medicines Agency has issued recommendations on testing patients for DPD deficiency before they are treated with fluorouracil or related medicines.
You may also be interested in...
Biologicals Join List Of EU Medicines Requiring Nitrosamine Evaluation
Although biological medicines carry a very low risk of being contaminated by nitrosamine impurities, the EMA says the possibility cannot be ruled out.
Indian Firms Take Different Paths On Ranitidine
A double blow to ranitidine medicines – suspension in the EU and a withdrawal request in the US – has caused Indian API and formulation manufacturers to recalibrate their strategies. Amid uncertainty over future prospects for the gastrointestinal drug, Strides is considering a relaunch in the US while Solara is reassigning part of its capacity to manufacture other APIs.
Ranitidine Blow Sees Indian Firms Take Different Paths
A double blow to ranitidine medicines - suspension in the EU and a withdrawal request in the US - has caused Indian API and formulation manufacturers to recalibrate their strategies. Amid uncertainty over future prospects for the gastrointestinal drug, Strides is considering a relaunch in the US while Solara is reassigning part of its capacity to manufacture other APIs.